(PDCs) may enhance the delivery of by addressing key challenges in their clinical translation.
PDCs combine polymeric carriers and therapeutic agents for targeted delivery.
These conjugates could improve the stability and systemic circulation of nucleic acids.
PDCs may reduce immunogenicity and provide controlled release of therapeutic agents.
Applications of PDCs include treating cancer, immune disorders, and fibrosis.
Despite advancements, challenges in the clinical adoption of PDCs remain.
Simplified
The effective clinical translation of messenger RNA (mRNA), small interfering RNA (siRNA), and microRNA (miRNA) for therapeutic purposes hinges on the development of efficient delivery systems. Key challenges include their susceptibility to degradation, limited cellular uptake, and inefficient intracellular release. (PDCs) offer a promising solution, combining the benefits of polymeric carriers and therapeutic agents for targeted delivery and treatment. This comprehensive review explores the clinical translation of , focusing on polymeric drug conjugates. It investigates how these conjugates address delivery obstacles, enhance systemic circulation, reduce immunogenicity, and provide controlled release, improving safety profiles. The review delves into the conjugation strategies, preparation methods, and various classes of PDCs, as well as strategic design, highlighting their role in nucleic acid delivery. Applications of PDCs in treating diseases such as cancer, immune disorders, and fibrosis are also discussed. Despite significant advancements, challenges in clinical adoption persist. The review concludes with insights into future directions for this transformative technology, underscoring the potential of PDCs to advance nucleic acid-based therapies and combat infectious diseases significantly.
Full Text
We can’t show the full text here under this license.
